As of 2024-12-14, the Intrinsic Value of Jazz Pharmaceuticals PLC (JAZZ) is
172.72 USD. This JAZZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 123.04 USD, the upside of Jazz Pharmaceuticals PLC is
40.40%.
The range of the Intrinsic Value is 84.70 - 575.50 USD
172.72 USD
Intrinsic Value
JAZZ Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
84.70 - 575.50 |
172.72 |
40.4% |
| DCF (Growth 10y) |
143.70 - 796.39 |
261.31 |
112.4% |
| DCF (EBITDA 5y) |
42.08 - 88.87 |
52.07 |
-57.7% |
| DCF (EBITDA 10y) |
88.48 - 159.25 |
106.80 |
-13.2% |
| Fair Value |
63.76 - 63.76 |
63.76 |
-48.18% |
| P/E |
45.01 - 212.69 |
115.29 |
-6.3% |
| EV/EBITDA |
93.51 - 181.87 |
112.89 |
-8.2% |
| EPV |
129.40 - 207.46 |
168.43 |
36.9% |
| DDM - Stable |
72.84 - 278.10 |
175.47 |
42.6% |
| DDM - Multi |
48.93 - 146.96 |
73.62 |
-40.2% |
JAZZ Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
7,437.77 |
| Beta |
0.66 |
| Outstanding shares (mil) |
60.45 |
| Enterprise Value (mil) |
11,331.44 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.92% |
| Cost of Debt |
6.18% |
| WACC |
6.17% |